Phenibut BST tabl. 250mg in 10×2 box

Name Phenibut BST. Forms of release Tablets. INN Phenibut. Active ingredient: γ-amino-β-phenylbutyric acid hydrochloride 250 mg. Excipients: lactose monohydrate, modified corn starch, corn starch, stearic acid. Pharmacotherapeutic group Other psychostimulants and nootropics. Code ATX: N06BX22 Pharmacological properties Pharmacodynamics The active substance Phenibut BST (γ-amino-β-phenylbutyric acid hydrochloride) can be considered as a derivative of γ-aminobutyric acid (GABA) or as a derivative of β-phenylethylamine. Phenibut BST has nootropic activity, and as a GABA derivative it has an anxiolytic (tranquilizing) effect. Does not affect cholinergic and adrenergic receptors. Phenibut BST lacks anticonvulsant activity. Phenibut BST lengthens the latent period of nystagmus and shortens its duration and severity. Pharmacokinetics The drug is well absorbed after oral administration and penetrates into all tissues of the body, overcomes the blood-brain barrier. About 0.1% of the administered dose of the drug penetrates into the brain tissue, and in young and old people to a much greater extent. Metabolized in the liver – 80-95%, to pharmacologically inactive metabolites. About 5% is excreted by the kidneys unchanged. With repeated administration, cumulation is not observed. Indications for use Apply with increased nervous excitability (neurasthenia) and sleep disorders. In children – for the treatment of stuttering, tics. Dosage and administration Phenibut BST tablets are taken orally after meals with water. The duration of the course of treatment is determined by the doctor, taking into account the disease, the tolerance of the drug and the effect achieved. The tablet can be divided into two equal doses. With increased nervous excitability (neurasthenia) and sleep disorders 500 mg 3 times a day. Higher single doses: for adults – 750 mg, for people over 60 years old – 500 mg. The course of treatment is 2-3 weeks. If necessary, the course can be extended up to 4-6 weeks. Use in children and adolescents (for the treatment of stuttering, tics) For children under the age of 8 years, the dose is 125 mg 3 times a day, at the age of 8 to 14 years – 250 mg 3 times in a day. Children over 14 years of age are prescribed doses for adults. The use of tablet dosage forms in children under 6 years of age is accompanied by an increased risk of aspiration, since complete control of the swallowing reflex develops by the age of six. For use in children under 6 years of age, preparation of a powder or suspension in a pharmacy is recommended for dosing accuracy. Patients with impaired liver function In patients with impaired liver function, high doses of Phenibut BST may cause a hepatotoxic effect. Patients in this group are prescribed lower doses of the drug under the control of liver function. Patients with impaired renal function The use of the drug is contraindicated in patients with acute renal failure. With prolonged use in patients with impaired liver and / or kidney function, it is necessary to monitor indicators of kidney and liver function. appointment, take the medicine as soon as you remember, but skip if it is almost time for your next dose. Never take double doses to make up for a missed dose. Adverse reactions Phenibut BST, like other medicines, may cause side effects that may not occur in all patients. Classification of adverse reactions according to the frequency of development: very often (≥1/10); often (≥1/100 to <1/10); infrequently (≥1/1000 to <1/100); rarely (≥1/10,000 to <1/1000); very rarely (<1/10,000); not known (cannot be determined from the available data). Immune system disorders: not known - hypersensitivity reactions (including urticaria, pruritus, erythema, rashes, angioedema, swelling of the face, swelling of the tongue). Nervous system disorders: not known - drowsiness at the beginning of treatment, increased irritability, agitation, anxiety, headache, dizziness (when taken in doses of more than 2 g per day, the severity of side effects decreases with dose reduction). Gastrointestinal tract disorders: not known - nausea (at the beginning of treatment). Skin and subcutaneous tissue disorders: rarely - allergic reactions (skin rash, itching). Liver and biliary tract disorders: not known - hepatotoxicity (with prolonged use of high doses). Case reports received the development of emotional instability and sleep disturbances in children after taking the drug. There is no dependence on the drug, Phenibut BST does not cause "withdrawal". The literature contains data on individual cases of addiction caused by the use of the drug. In case of adverse reactions, including those not listed in the instructions for use, you should consult a doctor. Contraindications Hypersensitivity to the active substance or excipients of the drug. Acute renal failure. Pregnancy and lactation. Overdose There have been no reports of overdose. Symptoms: drowsiness, nausea, vomiting, dizziness. With prolonged use of high doses, eosinophilia, arterial hypotension, impaired renal activity, fatty degeneration of the liver (intake of more than 7 g) may develop. Treatment: gastric lavage, symptomatic treatment. There is no specific antidote. Precautions Caution should be exercised in patients with erosive and ulcerative diseases of the gastrointestinal tract due to the irritant effect of the drug. These patients are prescribed lower doses of the drug. With prolonged use, it is necessary to monitor peripheral blood and liver function. If the symptoms of the disease persist or worsen while taking the drug, you should consult a doctor. Phenibut BST 250 mg tablets contain lactose. Do not use in patients with congenital galactose intolerance, lactase deficiency or glucose-galactose malabsorption. Use during pregnancy and lactation Use during pregnancy and lactation is contraindicated, because. there are no adequate and well-controlled clinical studies on the safety of the drug during these periods. In experimental animal studies, no mutagenic, teratogenic and embryotoxic effects of the drug have been established. Influence on the ability to drive vehicles and maintain mechanisms Patients who experience drowsiness, dizziness or other disorders of the central nervous system should not drive vehicles or maintain mechanisms during treatment. Interaction with other drugs Combining the drug Phenibut BST with other psychotropic drugs requires prior consultation with a doctor and supervision of a doctor during treatment. It is not recommended to prescribe the drug Phenibut BST with carbamazepine, oxcarbazepine or MAO inhibitors. Shelf life 4 years. Do not use the medicinal product after the expiration date indicated on the package. Storage conditions Store in a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Upakovka10 tablets in a blisters of polyvinyl chloride film and aluminum foil. 2 blisters (20 tablets) in a carton pack with enclosed instructions for use. Terms of dispensing from pharmacies By prescription. Buy Phenibut BST tabl.250mg in a cell.pack 10x2